Immune checkpoint inhibitors (ICIs) have transformed oncology but IV administration can cause infusion reactions, require line access, and add staff and chair-time burden. Recently, atezolizumab and nivolumab were approved for subcutaneous use, with more in development. In this podcast, oncologists Lucio Gordan, MD, and Saby George, MD, discuss the burden of IV ICIs, how subcutaneous options address these issues, compare efficacy and safety, and highlight the role of multidisciplinary teams in treatment decisions and workflow optimization.